Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
150.8 USD | -0.84% |
|
-0.70% | +56.24% |
Jun. 26 | Monetary policy is getting even more confusing | ![]() |
Jun. 26 | Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172 | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.24% | 14.38B | |
+20.68% | 127B | |
+25.52% | 117B | |
+25.56% | 27.77B | |
-19.82% | 20.44B | |
-14.36% | 16.62B | |
-13.70% | 15.92B | |
-46.67% | 14.94B | |
+12.47% | 14.74B | |
+146.29% | 12.42B |
- Stock Market
- Equities
- SRPT Stock
- News Sarepta Therapeutics, Inc.
- Transcript : Sarepta Therapeutics, Inc., Q2 2023 Earnings Call, Aug 02, 2023